Biomarkers in Arthroplasty: A Systematic Review by Mertens, Marty T & Singh, Jasvinder A
92 The  Open  Orthopaedics  Journal, 2011, 5, 92-105   
 
  1874-3250/11  2011 Bentham Open 
Open Access 
Biomarkers in Arthroplasty: A Systematic Review 
Marty T. Mertens
1, Jasvinder A. Singh
*,1,2,3,4 
1Rheumatology Section, Medicine Service and 
2Center for Chronic Disease Outcomes Research at the VA Medical 
Center, Minneapolis, MN, USA 
3Division of Rheumatology, Department of Medicine, University of Minnesota, Minneapolis, MN, USA 
4Departments of Health Sciences Research and Orthopedics, Mayo Clinic School of Medicine, Rochester, MN, USA 
Abstract: We performed a systematic review of all MEDLINE-published studies of biomarkers in arthroplasty. Thirty 
studies met the inclusion criteria; majority evaluated biomarkers for osteolysis, aseptic prosthetic loosening, and 
prosthetic infections. Four studies reported an elevated Cross-linked N-telopeptides of type I collagen (urine or serum) in 
patients with osteolysis or aseptic prosthetic loosening when compared to appropriate controls. Two or more studies each 
found elevated C-reactive protein, erythrocyte sedimentation rate, and interleukin-6 in patients with infected prosthetic 
joints compared to controls. Most other biomarkers were either examined by single studies or had inconsistent or 
insignificant associations with outcomes. We conclude that the majority of the biomarkers currently lack the evidence to 
be considered as biomarkers for arthroplasty outcomes. Further studies are needed. 
Keywords: Biomarkers, arthroplasty, systematic review. 
INTRODUCTION 
  Total hip and knee arthroplasty (THA and TKA) 
represent a major advance in the treatment of refractory 
hip/knee joint pain. TKA and THA are performed very 
commonly and are projected to increase dramatically in 
numbers in the next two decades [1]. Increasing longevity, 
earlier age at arthroplasty, and excellent pain and functional 
outcomes with these procedures are cited as reasons for the 
increasing incidence of these procedures. A number of 
patients, however, have suboptimal outcomes. Complications 
may include refractory pain, peri-prosthesis osteolysis with 
aseptic loosening, heterotopic ossification, and infection, 
which may result in a failed arthroplasty. Evaluation for 
complications of arthroplasty are primarily clinical, with few 
prognostic or diagnostic tests easily available that allow 
early identification of this subgroup of patients with 
suboptimal outcomes. 
  Biomarkers are objective indicators of biologic 
processes, pathologic processes or pharmaceutical responses 
to therapeutic interventions [2]. A number of studies have 
assessed the prognostic and diagnostic utility of biomarkers 
in improving evaluation of outcomes following arthroplasty. 
The purpose of this systematic review is to summarize the 
data from the literature regarding biomarkers for arthroplasty 
outcomes. We specifically evaluated if there are any valid 
biomarkers for osteolysis or loosening of the prosthesis, 
prosthetic infections, pain/stiffness following arthroplasty, or 
other complications following arthroplasty. 
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METHODS 
Study Design 
  All English language studies investigating biomarkers for 
various clinical outcomes of arthroplasty in humans were 
included in this review. Exclusion criteria included case 
reports, meta-analyses, and reviews. Studies that evaluated 
short term post-operative changes in biomarkers, biomarker 
changes related to medical therapies following arthroplasty, 
thromboembolic outcomes, and studies limited to pathology 
only were excluded as they were felt to be beyond the scope 
of this review. 
Search Methods for Identification of Studies 
  A Cochrane librarian searched the MEDLINE electronic 
bibliographic database up to July 2008 using the MeSH 
terms “arthroplasty”, “replacement” and “biomarkers” and 
similar terms. The reference lists of identified publications 
were reviewed to identify any additional studies (Appendix 1 
and 2). 
Data Collection 
  Two reviewers (MM and JS) independently applied 
inclusion/exclusion criteria to all potential studies and 
extracted data and outcomes using a standardized form. Any 
disagreements were resolved by discussion between the two 
reviewers, referring to a third party if necessary. Review 
authors were not blinded to any features of studies, since 
unblinding has minimal impact on selection bias [3]. 
  From each study, we extracted the following data – (1) 
study population, (2) methods and details of any 
interventions, (3) type of arthroplasty and implant, knee vs 
hip vs other, cemented vs noncemented, primary vs revision, 
and (4) types of biomarkers evaluated. Outcome data were  
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extracted, where possible, as raw numbers, plus any 
summary measures where standard deviations or confidence 
intervals were given. If no raw results were available, 
specific outcomes were described in detail. 
RESULTS 
Eligible Studies 
  A total of 105 articles met initial criteria from the initial 
MEDLINE search completed in June 2007. The search was 
updated in July 2008 and a total of 149 articles were 
identified (Fig. 1). A total of 30 studies met inclusion/exclusion 
criteria, 26 from the original search and four additional studies 
from the reference lists of these studies. 
Osteolysis 
  A total of five studies evaluated biomarkers for osteolysis 
following knee or hip arthroplasty (summarized in Table 1). 
Most comparisons were made to populations with 
Table 1.  Summary of Biomarkers for Osteolysis 
 
Osteolysis  No Osteolysis  Healthy Control 
Outcome  Study  
(Hip, Knee, Both) 
n  Mean (SD)  n  Mean (SD)  p-Value  n  Mean (SD)  p-Value 
Collagen peptides                   
Urinary cross-linked 
N-telopeptide of type 
I collagen 
Antonioiu 2000 
(hip) 
11  NA 8
A  NA  p = 0.002  7  NA  p = 0.0297 
 
Von Schewelov 
2006 
(hip) 
33 
34 bone collagen 
equivalents 
(BCE)/nM 
creatinine 
(12) 
127
A 
29 BCE/nM 
Cr 
(15) 
p = 0.06       
Serum C-terminal 
telopeptide of type I 
collagen 
Arabmotlagh 2006 
(hip) 
53 
Significant correlation found between bone mineral density 
loss in ROI 7 at 1 year with week 3 CTX-1 values (p = 0.002)      
Chemokines, 
Cytokines & other                 
Interleukin (IL)-1 
Fiorto 2003 
(hip) 
8 
2.15pg/ml 
(1.37) 
 
10
A  2.26pg/ml 
(0.89) 
p = 0.96  17 
2.02pg/ml 
(1.25) 
p = 0.79 
 
Hernigou 1999 
(hip) 
6 “Undetectable”  10
B  NA NA  5  “undetectable” NA 
Tumor Necorsis 
Factor- 
Fiorto 2003 
(hip) 
8 
4.32pg/ml 
(5.2) 
10
A  3.84pg/ml 
(1.13) 
p = 0.62  17 
3.42pg/ml 
(2.12) 
p = 0.95 
 
Hernigou 1999 
(hip) 
6 “undetectable”  10
B  NA NA  5  “undetectable” NA 
IL-6 
Fiorto 2003 
(hip) 
8 
2.86pg/ml 
(1.95) 
10
A  4.58pg/ml 
(4.02) 
p = 0.24  17 
3.88pg/ml 
(2.72) 
p = 0.36 
 
Hernigou 1999 
(hip) 
6 
41pg/ml 
(17) 
10
B  22pg/ml 
(6.7) 
p = 0.002  5  NA  NA 
IL-11 
Fiorto 2003 
(hip) 
8 
0pg/ml 
(0) 
10
A  1.22pg/ml 
(2.57) 
p = 0.27  17 
18.69pg/ml 
(10.55) 
p = 0.001 
transforming growth 
factor (TGF)- 
Fiorto 2003 
(hip) 
8 
23175pg/ml 
(8774) 
10
A  21120pg/ml 
(13657) 
p = 0.50  17 
23615pg/ml 
(10681) 
p = 0.88 
matrix 
metalloproteinase-1 
(MMP-1) 
Fiorto 2003 
(hip) 
8 
3.69pg/ml 
(1.75) 
10
A  4.10pg/ml 
(1.44) 
p = 0.50  17 
3.31pg/ml 
(1.7) 
p = 0.52 
prostaglandin E-2 
(PGE-2) 
Fiorto 2003 
(hip) 
8 
1330pg/ml 
(1097) 
10
A  2021pg/ml 
(1046) 
p = 0.14  17 
2893pg/ml 
(782) 
p = 0.005 
Bone Alkaline 
Phosphatase (ALP) 
Arapmotlagh 2006 
(hip) 
53 
No significant correlation found between bone mineral density 
loss in ROI 7 at 1 year with bone ALP values      
Osteocalcin 
Arapmotlagh 2006 
(hip) 
53 
No significant correlation found between bone mineral density 
loss in ROI 7 at 1 year with osteocalcin values      
C-reactive protein 
Hernigou 1999 
(hip) 
6 
10mg/L 
(2.4) 
10
B  7.7mg/L 
(2.8) 
p = 0.135  5  NA  NA 
AArthroplasty without osteolysis. 
BArthroplasty without osteolysis, >10 years post-op. 
ROI = region of interest. 94    The Open Orthopaedics Journal, 2011, Volume 5  Mertens and Singh 
arthroplasty with no osteolysis and to healthy controls 
without arthroplasty. 
 Collagen  telopeptides:  Three studies evaluated collagen 
telopeptides as biomarkers for osteolysis following hip 
arthroplasty. Antoniou et al. [4] reported significantly higher 
urinary cross-linked N-telopeptides of type-T collagen in 
patients with osteolysis following hip arthropathy compared 
to controls. von Schewelov et al. [5] found a near significant 
increase in urinary cross-linked N-telopeptide in the 
osteolysis versus non-osteolysis group (p=0.06), which 
became significant after adjusting for age, gender, and time 
after surgery. Arabmotlagh et al. [6] found serum C-terminal 
telopeptides of type I collagen 3 weeks post-operatively to 
be significantly correlated with bone loss one year after hip 
arthroplasty. 
 Interleukin-1 (IL-1) and Tumor Necrosis Factor-alpha 
(TNF-): Neither of the two studies that evaluated serum IL-
1    or TNF-  as a biomarker for osteolysis following hip 
arthroplasty found a significant difference between patients 
with osteolysis compared to controls [7, 8]. 
 IL-6:  Two studies [7, 8] evaluated IL-6 as a biomarker 
for osteolysis following hip arthroplasty. Hernigou et al. [8]  
 
Fig. (1). Summary of screening of eligible studies. 
149 articles identified with 
updated search up to July 2008 
 
___ excluded from abstract: 
   – foreign language 
   – duplicate studies  
   – did not involve arthoplasty 
   – non-human subjects 
  1 - thrombosis outcomes 
59 studies for full-text evaluation 
33 excluded from full-text: 
  13 - tissue pathology outcomes  
  5 - osteoarthritis patients 
  4 - post-operative changes only 
  3 - no clinical outcomes measured
  3 - markers for therapies of  
        arthroplasty complications 
   1 - reviews 
  1 - no biomarkers measured 
  1 - hip fracture patients 
  1 - not specific to arthroplasty 
  1 - individual data only 
4 studies added from 
evaluation of review of 
full-text studies 
30 studies included in this review Biomarkers in Arthroplasty  The Open Orthopaedics Journal, 2011, Volume 5    95 
   
Table 2.  Summary of Biomarkers for Loosening of Prosthesis 
 
Loosening Non-Loosened
A   Healthy  Control   
Outcome  Study (Hip, 
Knee, Both)  n  Mean (SD)  n  Mean (SD)  p-Value  n  Mean (SD)  p-Value 
Collagen peptides                   
Serum C-terminal 
propeptide of type 
I procollagen 
Schneider 
1998 
(hip) 
50 107.5  ng/ml
# 
(70.4) 
50
  82.2 ng/ml
# 
(32.8) 
NS      
  Savarino 
2005 
(hip) 
21 98.40  ng/ml 
(57.47) 
18
  124.73 ng/ml 
(53.12)
 
p = 0.04  30  172.81 ng/ml 
(59.7) 
NA 
 Li  2004 
(knee) 
15
C   25
D  No statistical difference between unstable 
and stable joints from 3 – 24 months post-op 
(p = 0.79, ANOVA) 
    
Serum N-terminal 
propeptide of type 
I procollagen 
Wilkinson 
2003 
(hip) 
17
1 
18
2 
46.9 ug/ml
1 
(NA) 
45.6 ug/ml
2 
32
1, 
31
2, 
37.5 ug/ml
1 
(NA) 
38.0 ug/ml
2 
(NA) 
NS      
Serum cross-
linked N-terminal 
telopeptide 
Savarino 
2005 
(hip) 
21  22.9nM 
bone 
collagen 
equivalents 
(BCE)/L
* 
(6.05) 
18
  17.92nMBCE/L
* 
(4.24)
 
p = 0.02  30  17.99nMBCE/L
* 
(3.61) 
NA 
Serum cross-
linked C-terminal 
telopeptide 
Li 2004 
(knee) 
15
C   25
D  Statistically higher levels in unstable joints 
vs stable joints from 6 – 24 months post-op 
(p = 0.02, ANOVA) 
    
  Wilksinson 
2003 
(hip) 
17
1 
18
2 
0.43 ng/ml
1 
(NA) 
0.45 ng/ml
2 
(NA) 
32
1, 
31
2, 
0.33 ng/ml
1 
(NA) 
0.33 ng/ml
2 
(NA) 
NS      
Serum Type III 
procollagen 
peptide 
Moreschini 
1997 
(hip) 
9 NA 13
  NA NS       
Urine cross-linked 
N-telopeptide of 
type I collagen 
Schneider 
1998 
(hip) 
50 NA  50
  NA p  <0.0001       
  Wilkinson 
2003 
(hip) 
17
1 
18
2 
61.0nM 
BCE/mM 
Cr
1,* 
(NA) 
62.3nM 
BCE/mM 
Cr
2,* 
(NA) 
32
1, 
31
2, 
39.9 nM BCE/mM Cr
1,* 
(NA) 
42.8nM BCE/mM Cr
2,* 
(NA) 
p = 0.02
1 
NS
2 
    
Chemokines, 
Cytokines & other 
               
Tumor Necorsis 
Factor- 
Granchi 
1998 
(hip) 
35 0.06  pg/ml 
(0.35) 
     25  0 
(0) 
NS 
  Hundri-
Haspl 2006 
(both) 
50 32.7  pg/ml 
(32.4) 
50
  22.9 pg/ml 
(18.7) 
p <0.01  50  3.9 pg/ml 
(3.9) 
p <0.001 
Interleukin (IL)-1  Granchi 
1998 
(hip) 
35 0.33  pg/ml 
(0.59) 
     25  0.37  pg/ml 
(0.5) 
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(Table 2) contd….. 
Loosening Non-Loosened
A   Healthy  Control   
Outcome  Study (Hip, 
Knee, Both)  n  Mean (SD)  n  Mean (SD)  p-Value  n  Mean (SD)  p-Value 
  Hundri-
Haspl 2006 
(both) 
50 3.7  pg/ml 
(5.5) 
50
  1.5 pg/ml 
(2) 
p <0.001  50  0.7 pg/ml 
(1.1) 
p <0.001 
  Moreschini 
1997 
(hip) 
9  NA 
(detectible in 
4/9 pts) 
13
  NA (detectible in 1/13 pts)  NS      
IL-6  Granchi 
1998 
(hip) 
35 28.9  pg/ml 
(65) 
     25  35.3 
(45) 
NS 
 Streich  2003  23 3.97  pg/ml 
(5.33) 
23 4.08  pg/ml 
(6.11) 
NS      
IL-8  Hundri-
Haspl 2006 
(both) 
50 14.7  pg/ml 
(9) 
50
  8.1 pg/ml 
(4.7) 
p <0.001  50  4.2 pg/ml 
(1.3) 
p <0.001 
IL-2 receptor  Granchi 
1998 
(hip) 
35 86.6  pg/ml 
(35.5) 
     25  83.9  pg/ml 
(35) 
NS 
 Streich  2003  23 469.2U/ml 
(155.2) 
23 515U/ml 
(160.5) 
NS      
Granulocyte-
macrophage 
colony stimulating 
factor (GM-CSF) 
Granchi 
1998 
(hip) 
35 29.6  pg/ml 
(41.4) 
     25  4.4  pg/ml 
(10) 
NS 
 Streich  2003  23 0.21  pg/ml 
(1.0) 
23 not  detectible  NS       
Osteocalcin  Wilkinson 
2003 
(hip) 
17
1 
18
2 
22.2 ng/ml
1 
(NA) 
20.7 ng/ml
2 
(NA) 
32
1, 
31
2, 
19.0 ng/ml
1 
(NA) 
20.6 ng/ml
2 
(NA) 
NS      
  Schneider 
1998 
(hip) 
50 NA  50
  NA p  <0.02      
 Li  2004 
(knee) 
15
C   25
D  Statistically higher levels in unstable joints 
vs stable joints at 12 months post-op only  
(p = 0.03) 
    
Elastase Streich  2003  23 58.9  ng/ml 
(46.8) 
23 56.6  ng/ml 
(45.0) 
NS      
Hyaluronic acid  Moreschini 
1997 
(hip) 
9 779.3ug/L 
(475.8) 
13
  112.9ug/L 
(42.5) 
p <0.05       
Bone Alkaline 
Phosphatase 
Wilkinson 
2003 
(hip) 
17
1 
18
2 
32.6 U/L
1 
(NA) 
28.5 U/L
2 
(NA) 
32
1, 
31
2, 
27.9 U/L
1 
(NA) 
28.2 U/L
2 
(NA) 
NS      
  Schneider 
1998 
(hip) 
50 123.8  U/L
# 
(42.5) 
50
  110.4 U/L
# 
(28.0) 
NS      
Nuclear factor-kB 
ligand (RANKL) 
Granchi 
2006 
(hip) 
36 1483  pg/ml 
(1179) 
33 3312  pg/ml 
(2211) 
p <0.002  20  1606 pg/ml 
(1245) 
NS 
Osteoprotegerin  Granchi 
2006 
(hip) 
36 4198  pg/ml 
(286) 
33 2397  pg/ml 
(1632) 
p <0.0001  20  2586 pg/ml 
(1082) 
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(Table 2) contd….. 
Loosening Non-Loosened
A   Healthy  Control   
Outcome  Study (Hip, 
Knee, Both)  n  Mean (SD)  n  Mean (SD)  p-Value  n  Mean (SD)  p-Value 
Urine free 
deoxypyridinoline 
Wilkinson 
2003 
(hip) 
17
1 
18
2 
8.2nmol/mM 
Cr
1 
(NA) 
8.4nmol/mM 
Cr 
2 
(NA) 
32
1, 
31
2, 
7.6nmol/mM Cr
 1 
(NA) 
7.5nmol/mM Cr 
2 
(NA) 
NS      
Urine 
deoxypyridinoline 
Schneider 
1998 
(hip) 
50 NA  50
  NA p  <0.001      
urine pyridinoline  Schneider 
1998 
(hip) 
50 NA  50
  NA p  <0.001      
                  
Synovial 
Analyses:  
               
Osteocalcin  Synpniewska 
2002 
(hip) 
8 4.2  ng/ml
# 
(NA) 
29
B  22.6 ng/ml
# 
(NA) 
p = 0.01       
B-crosslaps  Synpniewska 
2002 
(hip) 
10 0.8  ng/ml
# 
(NA)
 
36
B  1.3 ng/ml
# 
(NA)
 
p = 0.004       
Interleukin (IL)-1  Kovacik 
2000 
(knee) 
20  6.25 pg/ml 
(4.34) 
7
B  0.25 pg/ml 
(0.01) 
p <0.0001       
 Nibrant  1999 
(hip) 
26 17  pg/ml
# 
(NA) 
12
  7 pg/ml
# 
(NA)
 
0.18      
IL-1  Synpniewska 
2002 
(hip) 
8 1.9  pg/ml
# 
(NA) 
10
B  1.4 pg/ml
# 
(NA) 
NS      
IL-6 Nibrant  1999 
(hip) 
27 652  pg/ml
# 
(NA)
 
1
  1800 pg/ml
# 
(NA)
 
NA      
IL-8  Synpniewska 
2002 
(hip) 
9 870  pg/ml
# 
(NA)
 
26
B  340 pg/ml
# 
(NA)
 
p = 0.01       
IL-10  Synpniewska 
2002 
(hip) 
9 14.3  pg/ml
# 
(NA)
 
24
B  4.0 pg/ml
# 
(NA)
 
p = 0.004       
Tumor Necorsis 
Factor- 
Nivbrant 
1999 
(hip) 
38 31  pg/ml
# 
(NA)
 
12 25  pg/ml
# 
(NA)
 
0.22      
Bone Alakaline 
Phosphatase 
Synpniewska 
2002 
(hip) 
7 68.7U/L
# 
(NA)
 
20
B  98.1U/L
# 
(NA)
 
p = 0.01       
TNF-related 
activation protein 
(TRAP) 
Kovacik 
2000 
(knee) 
20 51.12U/L 
(25.75) 
7
B  14.07U/L 
(3.90) 
p <0.0001       
Chitinase 3-like 
protein 1 (YKL-
40) 
Kawasaki 
2001 
(hip) 
5 3265  ng/ml
# 
(NA) 
19
B  886 ng/ml
# 
(NA) 
p = 0.015       
*Nanomoles of bone collagen equivalents. 
AArthroplasty without evidence of osteolysis or loosening, unless otherwise noted. 
BOA patients, undergoing primary arthroplasty. 
CPotentially unstable knees, determined by MTPM >0.2mm on radiostereometric analysis (RSA); 
DStable knees, determined by MTPM <0.2mm on RSA. 
1Femoral implant 
loosening. 
2Pelvic implant loosening. 
#Median values (means not provided). MTPM = the largest three-dimensional translation of the tibial component. 98    The Open Orthopaedics Journal, 2011, Volume 5  Mertens and Singh 
 
reported significantly higher IL-6 levels in patients with 
osteolysis compared to controls, while, in contrast, Fiorto et 
al. [7] did not find a significant difference in IL-6 levels with 
similar comparison groups. 
 Other:  Biomarkers evaluated by single studies included 
bone alkaline phosphatase (bone ALP) and osteocalcin [6]; 
IL-11, transforming growth factor-beta (TGF-  ), matrix 
metalloproteinase-1 (MMP-1) and prostaglandin E-2 (PGE-
2) [7]; and C-reactive protein (CRP) [8]. Only IL-11 was 
significantly lower in patients with osteolysis when 
compared to healthy controls and those without osteolysis. 
Loosening 
  A total of 14 studies evaluated biomarkers for loosening 
of the prosthesis following knee or hip arthroplasty 
compared to healthy controls or patients with non-loosened 
prostheses (summarized in Table 2). Nine studies evaluated 
serum biomarkers and five, synovial fluid biomarkers. 
Serum Biomarkers  
 Collagen  Telopeptides:  Five studies evaluated various 
collagen peptides as a biomarker for prosthetic loosening. 
Serum levels of a C-terminal propeptide of type I 
procollagen (PICP) were not significantly different between 
clinically loosened hip prosthetic joints and controls [9] or 
between unfixed vs fixed knee protheses [10]. However, 
Savarino et al. [11] demonstrated a significantly lower PICP 
concentrations in loosened hip prostheses compared to stable 
hip implants. Serum N-terminal propeptide of type I 
procollagen (PINP) levels did not differ between patients 
with hip prostheis loosening and controls [12]. 
 Savarino  et al. [11] reported significantly higher serum 
cross-linked N-terminal telopeptide (NTx) levels in loosened 
hip protheses compared to controls. Li et al. [10] found 
significantly higher levels of serum cross-linked C-terminal 
telopeptides (ICTP) in unfixed knee arthroplasties when 
compared to fixed joints. Conversely, Wilkinson et al. [12] 
found no difference in ICTP levels between patients with 
loosened hip prostheses and controls. Moreschini et al. [13] 
found no significant difference in type III procollagen 
peptide levels in patients with loosened hip prostheses when 
compared to controls with osteoarthritis. 
 Schneider  et al. [9] and Wilkinson et al. [12] both found 
significantly increased levels of urinary crosslinked N-
telopeptides of type I collagen in patients with loosened hip 
arthroplasty when compared to stable prostheses. 
 TNF-:  Two studies [14, 15] evaluated TNF- as a 
biomarker for loosening of arthroplasty. Hundri-Haspl et al. 
[15] noted significant increase in TNF- values in patients 
with loosened knee and hip arthroplasty when compared to 
controls, while Granchi et al. [14] found no difference in 
TNF- levels in similar comparison groups. 
 IL-1: Three studies [13-15] evaluated serum IL-1 as a 
biomarker for arthroplasty loosening. Hundri-Haspl et al. 
[15] noted significant increase in IL-1 in patients with 
loosened knee and hip arthroplasty when compared to 
controls. Granchi et al. [14] did not find a difference in IL-1 
when comparing loosened hip arthroplasty to healthy 
controls. However, on subgroup analysis, they found a   
 
significant increase in IL-1 in patients with loosened 
titaniumaluminium-vanadium (TiAIV) cemented hip 
prostheses in comparison to healthy controls as well as 
loosened cobalt-chromium (CrCoMo) hip implants 
(cemented and uncemented) and uncemented TiAIV 
implants. Moreschini et al. [13] reported detectable IL-1 in 
4 of 9 patients with loosened hip implants compared to only 
1 of 13 patients with fixed hip implant and 0 of 13 patients 
with OA prior to arthroplasty, though no statistical analysis 
was performed. 
 IL-6:  Two studies [14, 16] found no significant 
differences in IL-6 levels in patients with loosened hip 
arthroplasty compared to controls. 
  Granulocyte-macrophage colony stimulating factor (GM-
CSF): Streich et al. [16] demonstrated detectible levels of 
GM-CSF in only 1 of 23 patients with loosened hip 
arthroplasty and in 0 of 23 of fixed hip implant patients. 
Granchi  et al. [14] reported significantly higher levels of 
GM-CSF in patients with a loosened hip arthroplasty when 
compared to healthy controls. This significant increase was 
demonstrated in all subgroups (cemented/uncemented TiAIV 
implants, cemented CrCoMo implants) except loosened 
uncemented CrCoMo implants which were similar to 
controls. 
 Osteocalcin:  Schneider  et al. [9] reported significantly 
higher osteocalcin levels in loosened versus stable 
prostheses, while Wilkinson et al. [12] found no difference 
with the same comparison. Li et al. [10] found significantly 
higher osteocalcin levels in patients with potentially unstable 
knee prostheses compared to patients with stable implants at 
12 months, but no differences were noted at 24 months. 
  Bone alkaline phosphatase ( ALP):  Bone-specific ALP 
levels were similar in patients with and without loosening of 
hip prosthesis in two studies [9, 12]. 
 Urine  deoxypyridinoline:  Schneider  et al. [9] found 
significantly higher urine deoxypyridinonline levels in 
patients with loosened hip implants compared to stable 
implants, while Wilkinson et al. [12] reported no significant 
difference in similar comparison groups. 
 IL-2  receptor:  Two studies [14, 16] found no significant 
differences in IL-2 receptor concentrations in patients with 
prosthesis loosening compared to controls. 
 Other:  The evidence for each of the following was based 
on single studies. Significantly higher levels of 
osteoprotegerin (OPG) and RANKL [17], hyaluronic acid 
[13], urine pyridinoline [9] and IL-8 [15] were found in 
patients with loosened hip implants compared to their 
respective controls. Elastase levels were not significantly 
different between patients with loosened implant and controls 
[16]. 
Synovial Biomarkers  
  Four studies evaluated various biomarkers in synovial 
fluid as a marker for loosening of the prosthetic joint when 
compared to controls. 
 IL-1:  Nivbrant  et al. [18] found significantly higher 
synovial  IL-1  in loosened hip implants compared to 
osteoarthritis patients, but were similar to patients with fixed  
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Table 3.  Summary of Biomarkers for Infected Prostheses 
 
   Infected Prosthesis  Control Group   
Outcome  Study (Hip, Knee, Both)  n  Mean (SD)  n  Mean (SD)  p-Value 
Interleukin (IL)-6  Bottner 2007 
(both) 
21 48.2  pg/ml 
(58.9) 
57
A  10.6 pg/ml 
(24.2) 
p = 0.0001 
  Di Cesare 2005 
(both) 
17 50.3  pg/ml 
(40.9) 
41
A  3.2 pg/ml 
(3.6) 
p <0.01 
Tumor Necrosis Factor- 
(TNF-) 
Bottner 2007 
(both) 
21 39.7  ng/ml 
(23.4) 
57
A  23.5 ng/ml 
(13.3) 
p = 0.0011 
Procalcitonin Bottner  2007 
(both) 
21 1.5  ng/ml 
(3.3) 
57
A  0.1 ng/ml 
(0.4) 
p = 0.0033 
C-reactive protein (CRP)  Bottner 2007 
(both) 
21 12.0mg/dl 
(9.0) 
57
A  1.1mg/dl 
(1.5) 
p <0.0001 
  Di Cesare 2005 
(both) 
17 142.0mg/L 
(145.3) 
41
A  6.4mg/L 
(7.4) 
p <0.01 
 Nilsdotter  2007 
(hip) 
22 24mg/L
# 
(NA) 
56
B  <10mg/L
# 
(NA) 
p <0.001 
 Spangehl  1999 
(hip) 
prospective analysis of 142 revision hip arthoplasties:  CRP >10mg/L had sensitivity of 0.96 and 
specificity of 0.92 (specific data not provided) 
Erythrocyte sedimentation 
rate (ESR) 
Bottner 2007 
(both) 
21 63.8mm 
(24.4) 
57
A  19.9mm 
(18.9) 
p <0.0001 
  Di Cesare 2005 
(both) 
17 82.0mm 
(33.1) 
41
A  30.4mm 
(25.9) 
p <0.01 
 Nilsdotter  2007 
(hip) 
22 36mm
# 
(NA) 
55
B  14mm
# 
(NA) 
p <0.001 
 Spangehl  1999 
(hip) 
prospective analysis of 171 revision hip arthoplasties: ESR >30mm had sensitivity of 0.82 and 
specificity of 0.85 (specific data not provided) 
Bacterial Markers:              
IgG lipoteichoic acid  Rafiq 2000 
(both) 
15
D  64,000 titer 
(47,451) 
32
C  8469 titer 
(5136) 
p <0.0001 
IgM lipoteichoic acid  Rafiq 2000 
(both) 
15
D  3992 titer 
(4094) 
32
C  3533 titer 
(3136) 
p = 0.79 
ica A operon  Frank 2004  44
E  20/44 isolates (46%) 
with ica A 
23
F  7/23 isolates (30%) with ica A  p = 0.23 
 Frank  2004  31
G  17/31 isolates (55%) 
with ica A 
9
H  5/9 isolates (56%) with ica A  p = 1.0 
 Galdbert  2000 
(both) 
54
G  44/54 isolates (81.5%) 
with ica A 
23
I  4/23 isolates (17.4%) with ica A  p = 0.01 
Biofilm production  Galdbert 2000 
(both) 
54
G  34/54 isolates (62.9%) 
with biofilm production 
23
I  2/23 isolates (8.6%) with biofilm 
production 
 
Other operons  Galdbert 2000 
(both) 
54
G   23
I  no significant difference in frequency of the following 
operons: clfA, atlE, fbe, fnbA, cna 
Synovial markers:              
Cytokines  
(TNF-, IL-6, IL-1) 
Nilsdotter 2007 
(hip) 
17   47
B  significantly higher synovial levels in infected group vs 
aseptic loosening group (data not provided) 
Lactate Nilsdotter  2007 
(hip) 
17 5.8mmol/L
# 
(NA) 
45
B  5.4mmol/L
# 
(NA) 
p = 0.40 
AAseptic revision arthoplasties, 
BAseptic loosening of hip arthroplasty, 
CRecent closed fracture or osteoarthritis undergoing primary osteoarthritis of the hip, 
DInfections with gram 
positive bacteria, 
ECoagulase negative staph cultures from prosthetic infections, 
FCoagulase negative staph cultures from non-infected prostheses, 
GStaph epidermidis cultures from 
prosthetic infections, 
HStaph epidermidis cultures from non-infected prostheses, 
IStaph epidermidis cultures from skin flora on healthy individuals, 
#Median values (mean values not 
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hip prostheses. Similarly, Kovacik et al. [19] reported 
significantly higher synovial IL-1  levels in patients with 
loosened knee prostheses compared to osteoarthritis patients. 
 Other:  Nivbrant  et al. [18] demonstrated significantly 
higher synovial TNF- levels in loosened prosthetic hip 
joints when compared to OA patients, though not when 
compared to fixed hip implants. Synovial IL-6 levels were 
similar between all of these groups, though too few 
observations were available for comparisons. Kawasaki et al. 
[20] noted significantly higher YKL-40 levels, a growth 
factor for chondrocytes and fibroblasts, in failed hip implants 
when compared to OA patients, though these levels were 
similar to patients with osteonecrosis of the hip. Other 
biomarkers found to be significantly elevated in loosened 
prostheses when compared to OA patients in single studies 
were TNF-related activation protein (TRAP) concentrations 
[19], IL-8 [21], and IL-10 [21]. Lower concentrations of 
osteocalcin, B-crosslaps, and bone ALP were also noted in 
loosened hip prostheses when compared to OA patients in a 
single study [21]. IL-1 concentrations were similar in both 
groups [21]. 
Prosthetic Infections 
  A total of seven studies evaluated biomarkers for 
infection of the prosthesis following knee or hip arthroplasty 
(summarized in Table 3). Three studies, Rafiq et al. [22], 
Galdbert et al. [23], and Frank et al. [24] evaluated markers 
for specific infections of prosthetic joints and four studies 
evaluated diagnostic biomarkers for prosthetic infections. 
 C-reactive  protein (CRP) and Erythrocyte sedimentation 
rate (ESR): Three separate studies [25-27] each found 
significantly higher CRP and ESR levels in patients infected 
prosthetic joints compared to aseptic revisions. Spangehl et 
al. [28] prospectively analyzed patients undergoing hip 
revisions and noted a sensitivity of 0.96 and specificity of 
0.92 for CRP levels >10 mg/L for infected versus aseptic 
revisions. For ESR>30, the respective sensitivity was 0.82 
and specificity, 0.85. 
 IL-6:  Two studies [25, 26] each noted significantly 
higher levels of serum IL-6 in infected prosthetic joints when 
compared to aseptic joints undergoing revision arthroplasty. 
 Other  cytokines:  Bottner et al. [26] noted elevated levels 
of serum TNF- and procalcitonin in patients with infected 
prosthetic joints compared to aseptic prosthetic revisions. 
 Synovial  fluid  markers:  Nilsdotter  et al. [27] noted 
significantly higher synovial fluid concentrations of TNF-, 
IL-1, and IL-6 in those with infected prosthetic hip joints 
when compared to aseptic controls. 
 Bacterial  markers:  Galdbert et al. [23] evaluated bacterial 
genes from Staphylococcus epidermidis strains cultured from 
prosthetic infections as compared to S. epidermidis strains 
from skin flora of healthy controls. They found significantly 
greater frequency of biofilm production and the ica A operon 
in infected prostheses. In contrast, Frank et al. [24] found no 
difference in frequency of the ica A operon in coagulase-   
 
 
 
negative staph species cultured from prosthetic infections in 
comparison to strains obtained from prosthetic joints 
without evidence of infection. 
 Rafiq  et al. [22] reported significantly elevated titers of 
IgG to cellular lipoteichoic acid in patients with prosthetic 
joint infections as compared to patients with osteoarthritis or 
closed fractures. IgM titers were similar between these 
groups. 
OTHER OUTCOMES 
Pain/Stiffness 
   Hall et al. [29] found a significant correlation between 
peak CRP levels post-operatively and pain at time of 
discharge as well as between peak IL-6 levels post-
operatively and time to be able to ambulate 10 and 25m 
following hip arthroplasty. No significant correlations were 
found between CRP or IL-6 levels post-operatively to 1 and 
6 month Western Ontario and McMaster universities 
osteoarthritis index (WOMAC) values, a measure of 
arthritis-related disability. 
 Wozniak  et al. [30] prospectively found significantly 
higher nitrous oxide (NO) production from stimulated 
peripheral neutrophils 2 months and 2-3 years post-
operatively in patients with pain compared to patients 
without pain following primary knee or hip arthroplasty. 
Heterotopic Ossification  
  Wilkinson et al. [31] noted significantly greater levels of 
C-telopeptide of type-I collagen, osteocalcin, and N-terminal 
propeptide of type-I procollagen in patients who developed 
heterotopic ossification at 26 weeks when compared to those 
without ossification. No differences were noted in bone 
ALP, urinary cross-linked N-telopeptide of type-I collagen, 
and urinary free deoxypridinoline. 
Polyethyelene Wear  
 Messieh  et al. [32] noted a significant correlation 
between synovial lactate dehydrogenase (LDH) levels and 
polyethylene wear in eleven patients undergoing revision 
knee arthroplasty. 
Hospital Outcomes  
  Ackland et al. [33] prospectively noted patients with a 
preoperative CRP >3mg/L had a significantly longer mean 
hospital stay as compared to those with CRP <3 mg/L (7.5 
vs 6.0 days, respectively) following knee or hip arthroplasty. 
DISCUSSION 
  This systematic review of biomarkers in arthroplasty 
summarized the findings from 30 studies of clinical 
outcomes following knee and/or hip arthroplasty. Despite the 
enormous success rates of knee and hip arthroplasties, 
patients may face a number of potential complications post-
operatively and during long-term follow-up, including peri-
prosthetic osteolysis, implant loosening, and joint infections. 
Diagnostic and prognostic biomarkers have the potential to  
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provide an early, accurate, and noninvasive diagnosis of 
these undesired outcomes as well as help design 
interventions to prevent some of these complications. 
  The most frequently studied arthroplasty outcomes with 
regards to biomarkers were osteolysis and prosthesis 
loosening. Osteolysis and subsequent aseptic joint loosening 
is the most common reason for joint revision in hip 
arthroplasty in the United States. 
    In our review of the published literature, only cross-
linked Ntelopeptides of type I collagen (NTX-1) (serum or 
urine) was significantly associated with loosening/osteolysis, 
in more than two studies with appropriate controls (without 
loosening/osteolysis and/or healthy controls) [4, 9, 11, 12]. 
Von Schewelov et al. found an insignificant difference 
between NTX-1 levels in patients with presence of osteolysis 
when compared to controls (p = 0.06), though became 
significant after adjustment for age, gender, and time after 
surgery. 
  Serum cytokines, such as serum IL-1  or TNF-, that 
have been suspected to be associated with development of 
osteolysis and loosening [35-38] had inconsistent 
associations with loosened prostheses [14, 15] and no 
association with osteolysis [7, 8]. We postulate that this 
may be due to lack of well-designed studies rather than lack 
of association. A significant immunological response occurs 
in the periprosthetic tissue in many patients with prosthetic 
loosening, and it has been thought that this inflammatory 
process may contribute to the development of osteolysis and 
aseptic loosening [35-38]. Other biomarkers for osteolysis or 
prosthesis loosening were either studied by single studies or 
had inconsistent or insignificant differences. 
  Prosthetic infections lead to significant morbidity, are 
difficult to diagnose, and may lead to significant disability. 
CRP and ESR, both of which are currently used clinically in 
the diagnosis and follow-up of patients with prosthetic joint 
infections, were consistently found to be significantly 
elevated in septic prosthetic joints as compared to aseptic 
joint revision controls in a number of studies [25-28]. 
Interleukin-6 was consistently found to be elevated in septic 
prostheses as compared to aseptic revision controls [25, 26]. 
  A number of other arthroplasty outcomes included in this 
review, such as heterotopic ossification, pain following 
arthroplasty, post-operative hospital outcomes, and 
polyethylene wear, were evaluated only by one or two 
studies. Because of this, it is difficult to make adequate 
assessments for there potential use as biomarkers for these 
outcomes. 
  This review had a number of limitations, mostly related 
to limitations of the included studies. The large variability of 
the biomarkers measured in the included studies with only a 
few studies replicating the results for each biomarker in 
more than one study/population, limited our ability to draw 
conclusions for most biomarkers. The majority of the 
included studies were case control studies with small sample 
sizes, with half of the included studies containing <50 
patients. A number of these studies measured multiple 
biomarkers at multiple outcomes, making them prone to 
type I error, i.e., finding a positive result just by chance. 
Well-designed studies of larger, welldefined cohorts are 
needed to improve our understanding of the utility of these 
biomarkers in predicting arthroplasty outcomes. 
  In conclusion, this review evaluated 30 studies that 
measured different biomarkers for knee and hip arthroplasty 
outcomes. While a few biomarkers – namely cross-linked N-
telopeptides of type I collagen for prosthesis loosening or 
osteolysis and CRP, ESR, and IL-6 for infected prostheses – 
were found consistently significantly different from control 
groups in the included studies, most biomarkers lack the 
evidence to be considered adequate markers for the 
arthroplasty outcomes at the present time. However, this is 
an exciting area of research that has the potential to impact 
and improve arthroplasty outcomes. Further studies are 
necessary, likely with larger study populations and longer 
prospective follow-up, to determine which of these 
biomarkers will have clinical application in diagnosis and/or 
prognosis of arthroplasty outcomes. 
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Appendix 1. Search strategy for Systematic Review Performed in 2007 (Updated in July 2008) 
 
 
Database: Ovid MEDLINE(R) <1950 to July Week 4 2007> 
 
Search Strategy: 
 
--------------------------------------------------------------------------- 
 
1     Biological Markers/ or biomarkers.mp. (79469) 
 
2     exp Arthroplasty, Replacement, Knee/ or exp Arthroplasty, Replacement/ or exp Arthroplasty, Replacement, Hip/ or exp  
Arthroplasty/ or exp Arthroplasty, Replacement, Finger/ or exp Joint Prosthesis/ or arthroplasty.mp. (39802) 
 
3     1 and 2 (125) 
 
4     limit 3 to english language (105) 
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Appendix 2.  Summary of the Included Studies 
 
Study  Study Design/ 
Level of Evidence  Comparisons Outcomes  Other  Notes 
Antonioiu 2000  case control 
study/Level III 
Hip osteolysis (n = 11), hip arthroplasty 
without osteolysis (n = 8), healthy 
controls (n = 7), hip osteolysis 
following alendronate therapy x6 weeks 
(n = 10) 
Urinary cross-linked N-
telopeptide of type I collagen;  
Longer average time from 
original operation in 
osteolysis group (8.8yrs) 
vs. fixed implants 
(2.4yrs) 
Von Schewelov 2006  case control 
study/Level III 
Hip osteolysis (n = 33); hip arthroplasty 
without osteolysis (n = 127) 
urinary cross-linked N-
telopeptide of type I collagen 
Post-operative time in 
osteolysis was 73 months 
vs. 42 months in non-
osteolysis group. 
Arabmotlagh 2006  Prospective cohort 
study/Level II 
53 patients with unilateral THA for OA; 
followed with bone density scans on 2, 
4, 6, and 12mos post-op and correlated 
to marker measured at 3, 6, 16, and 24 
weeks post-op. 
Serum C-terminal telopeptide 
of type I collagen; bone ALP, 
osteocalcin 
Numerous comparisons 
from BMD and 
biomarkers lessen 
reliability of findings. 
Hernigou 1999  case control 
study/Level III 
Hip osteolysis, >10yrs postop (n = 6); 
hip arthroplasty without osteolysis, 
>10yrs post-op (n = 10); hip 
arthroplasty without osteolysis, <6yrs 
post-op (n = 6); healthy controls (n = 5) 
IL-B, TNF-a, IL-6, CRP   
Fiorito 2003  case control 
study/Level III 
Hip osteolysis (n = 8); hip arthroplasty 
without osteolylsis (n = 10); healthy 
controls (n = 17) 
IL-1B, IL-6, TNF-a, TGF-B, 
PGE-2, MMP-1, IL-11 
 
Schneider 1998  case control 
study/Level III 
Aseptic loosening of hip implant  
(n = 50); fixed hip implant (n = 50) 
Bone ALP, osteocalcin, serum 
C-terminal propeptide of type 
I procollagen, urine cross-
linked N-telopeptide of type I 
collagen, urine pyridinoline, 
urine deoxypyridinonline 
 
Savarino 2005  case control 
study/Level III 
Aseptic loosening of hip implant  
(n = 21), fixed hip implant (n = 18), OA 
patients at time of primary arthroplasty 
(n = 17), healthy controls (n = 30) 
Serum cross-linked N-
telopeptide of type I collagen, 
serum C-terminal propeptide 
of type I procollagen 
Healthy controls not 
matched for age or gender 
and not used in statistical 
comparisons 
Li 2004  prospective cohort 
study/Level II 
45 patients followed prospectively after 
TKA; biomarker measured at 1 week 
and 3, 6, 12, and 24 months post-op; 
compared to quality of fixation 
measured by RSA
1 – MTPM 
2 >0.2mm 
represented unstable fixation, <0.2mm 
represented stable fixation 
serum C-terminal propeptide 
of type I procollagen; serum 
cross-linked C-terminal 
telopeptide of type I collagen; 
osteocalcin 
A part of an 80 patient 
randomized prospective 
study comparing 
cemented to uncemented 
fixation of tibial 
component for TKA, 45 
agreed for blood tests; 
excluded patients without 
RSA data at 1 or 2 years 
(5 patients) 
Wilkinson 2003 
case control 
study/Level III 
Aseptic loosening of hip implant  
(n = 26); stable fixation of hip implant 
(n = 23) 
Bone ALP, serum cross-linked 
C-terminal telopeptide, 
osteocalcin, serum N-terminal 
propeptide of type I 
procollagen, urine cross-linked 
N-telopeptide of type I 
collagen, free 
deoxypyridinoline 
Only provided data for 
either femoral or pelvic 
loosening when compared 
to fixed implants 
Moreschini 1997 
case control 
study/Level III 
Aseptic loosened hip prosthesis (n = 9); 
fixed hip prosthesis (n = 13); OA 
patients prior to primary arthroplasty  
(n = 13) 
Hyaluronic acid, IL-1B, type 
III procollagen peptide   
Granchi 1998 
case control 
study/Level III 
Aseptic loosening of hip prosthesis  
(n = 35), healthy controls (n = 25) 
IL-1a, IL-1B, IL-6, GM-CSF, 
IL-2 receptor, TNF-a 
Differentiated failed 
arthoplasties to those with 
CrCoMo or TiAIV 
components 
Hundri-Haspl 2006 
case control 
study/Level III 
Large joint implant loosening (n = 50), 
large joint arthroplasty without 
loosening (n = 50), candidates for 
arthroplasty from advanced OA  
(n = 50), healthy controls (n = 50) 
IL-1B, IL-8, TNF-a 
Specific type of large 
joint prostheses not 
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(Appendix 2) contd….. 
Study  Study Design/ 
Level of Evidence  Comparisons Outcomes  Other  Notes 
Streich 2003  case control 
study/Level III 
Aseptic loosening of hip prosthesis  
(n = 23), fixed hip prosthetic implant  
(n = 23) 
IL-6, GM-CSF, elastase  Significantly more males 
in healthy donors 
Granchi 2006  case control 
study/Level III 
Aseptic loosening of hip implant  
(n = 36), fixed hip implant (n = 33), 
severe OA prior to arthroplasty (n = 39), 
healthy subjects (n = 20) 
Osteoprotegerin, RANKL 
Significantly more males 
in healthy donors; 
significantly longer 
duration for post-op 
evaluation in loosening 
(112 mos) vs. stable joint 
(32 mos) 
Synpniewska 2002  case control 
study/Level III 
aseptic loosening of hip implant  
(n = 10); primary OA patients 
undergoing primary arthroplasty  
(n = 39) 
synovial levels: osteocalcin, 
B-crosslaps, IL-1a, IL-8, IL-10 
no fixed arthroplasty 
control group; excluded 
patients from analysis if 
missing outcome data 
Kovacik 2000  case control 
study/Level III 
hip implant revisions (n = 20); primary 
OA patients undergoing primary 
arthroplasty (n = 7) 
synvoial levels: TRAP, IL-1B  does not specific reasions 
for hip implant revions 
Nivbrant 1999  case control 
study/Level III 
loose hip prosthesis (n = 38), fixed hip 
arthroplasty (n = 12); OA patients 
undergoing primary arthroplasty  
(n = 38) 
synovial levels: IL-1B, TNF-a, 
IL-6 
mean time from 
implantation for loose 
prosthetics was 9.8yrs vs. 
2.8yrs in fixed implant; 
excluded patients from 
analysis if missing data; 
median data only 
Kawasaki 2001  case control 
study/Level III 
loosened hip prosthesis (n = 5), OA 
patients from primary hip dysplasia  
(n = 19), osteonecrosis of femoral neck 
(n = 21) 
synovial levels: YKL-40 
average age for OA 
patients was 48 vs. 63 in 
loosed implant group; 
median data only 
Nildotter 2007  case control 
study/Level III 
infected hip implants (n = 25), loosened 
hip implant (n = 60), OA patients 
undergoing primary arthroplasty  
(n = 46) 
synovial levels: lactate, TNF-
a, IL-1B, IL-6 
serum levels: 
CRP, ESR, IL-6, TNF-a, IL-
1B 
no data provided on 
serum cytokine levels 
collected; no comparisons 
to OA control group 
provided; excluded 
patients from analysis if 
missing data 
Bottner 2007  case control 
study/Level III 
septic revision for large joints (n = 21); 
aseptic revision of large joints (n = 57) 
CRP, ESR, IL-6, TNF-a, 
procalcitonin 
Knee/hip revisions: 5/16 
for septic, 23/34 for 
aseptic 
Frank 2004  case control 
study/Level III 
staph cultures from prosthetic joint 
infections compared to coag (-) staph 
cultures from non-prosthetic joint 
infections 
icaADBC operon   
Galdbert 2000  case control 
study/Level III 
staph epidermidis strains from 
prosthetic infections (n = 54), staph 
epidermidis strains from skin flora from 
8 healthy individuals 
ica operon, biofilm 
production, genes: clfA, atlE, 
fbe, fnbA, cna 
 
Di Cesare 2005  case control 
study/Level III 
58 patients undergoing reoperation of 
hip or knee: 17 patients with septic 
prosthetic infection; 41 patients without 
evidence of infection 
CRP, ESR, IL-6   
Rafiq 2000 
case control 
study/Level III 
patients with prosthetic infection from 
gram positive organisms (n = 15), 
control group of 32 patients – 21 with 
closed fracture, 11 with primary OA 
IgG and IgG to lipoteichoic 
acid   
Spangehl 1999 
prospective cohort 
study/Level II 
prospectively evaluated 178 patients 
undergoing revision hip replacements 
determined specificity, 
sensitivity for CRP, ESR in 
prosthetic infections 
no specific data provided 
for comparison analysis; 
excluded patients from 
analysis if missing data 
Hall 2001 
prospective 
study/Level II  102 patients undergoing primary THA 
serum levels: norepinephrine, 
epinephrine, cortisol, IL-6, 
CRP; pain, function, and 
WOMAC
3 at 1 and 6 months;  
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